
The Cigna Group (CI): Refocusing on Core Strengths Amidst Sector Headwinds


Executive Summary & Investment Recommendation

A HOLD rating is initiated for The Cigna Group (CI) with a 12-month price target of $345.00. The company is executing a significant strategic transformation, marked by the divestiture of its government-sponsored businesses to intensify focus on its primary growth driver, the Evernorth Health Services platform, and its stable Cigna Healthcare commercial segment.1 This long-term strategy to de-risk the portfolio and concentrate on core competencies is viewed constructively. However, near-term upside appears limited by sector-wide headwinds and specific company pressures.
The managed care organization (MCO) sector is currently navigating a period of elevated medical cost trends, a challenge reflected in Cigna's year-over-year increase in its Medical Care Ratio (MCR) for the second quarter of 2025.3 Concurrently, the Evernorth segment, while a powerful engine for growth, faces a persistent overhang from regulatory and legislative scrutiny aimed at the Pharmacy Benefit Manager (PBM) industry, which could impact future profitability.5 The market's negative reaction to Cigna's second-quarter earnings beat—where the stock declined despite exceeding revenue and EPS expectations—underscores a shift in investor focus from top-line growth to margin stability and predictability.6
With the stock trading at a forward price-to-earnings (P/E) multiple of approximately 10.4x our 2026 earnings per share (EPS) estimate, the current valuation seems to appropriately balance the compelling growth narrative of Evernorth against these tangible near-term risks. This equilibrium supports a neutral stance until there is greater clarity on medical cost stabilization and the PBM regulatory landscape.

Recommendation & Valuation Summary


Rating
HOLD
Current Price (July 9, 2025)
$308.22 8
Price Target (12-Month)
$345.00
Potential Upside
+11.9%
Market Cap
~$81.5 Billion 9
FY 2025E Adj. EPS
$29.70
FY 2026E Adj. EPS
$33.10
P/E on FY 2025E
10.38x
P/E on FY 2026E
9.31x


Investment Thesis


The Bull Case: Evernorth's Dominance and Shareholder Returns Create Compelling Value

The bull thesis for Cigna centers on the strategic clarity and financial benefits of its recent portfolio realignment. Proponents argue that the divestiture of government-focused businesses de-risks the overall enterprise and allows management to concentrate on its most potent competitive advantage: the integrated Evernorth platform.5 Evernorth, anchored by the formidable Express Scripts PBM, is a market leader in pharmacy benefits, specialty pharmacy, and care solutions. This segment consistently delivers strong double-digit revenue growth and substantial, durable cash flows, forming the core of Cigna's growth story.3
Furthermore, the sale of the Medicare Advantage business for approximately $4.8 billion unlocks a significant amount of capital.1 Management has demonstrated a commitment to returning this capital to shareholders through an aggressive share repurchase program, which provides a direct and powerful tailwind for EPS accretion.1 With a forward P/E multiple below 10x, bulls contend that the stock is significantly undervalued.13 They argue the market is overly discounting the persistent regulatory chatter around PBMs and is failing to assign an appropriate valuation to the high-quality, high-growth Evernorth asset. This view is supported by a strong Wall Street consensus, with a majority of analysts rating the stock a "Buy" and average price targets suggesting a potential upside of over 20%.15

The Bear Case: Margin Pressure and Regulatory Overhang Present Unavoidable Risks

The bearish perspective emphasizes the structural headwinds facing the entire MCO sector. Critics argue that rising medical utilization is not a transient issue but a persistent trend that will continue to compress margins in the Cigna Healthcare insurance segment.6 The year-over-year increase in the second-quarter MCR is viewed as confirmation of this trend, making it challenging for the company to deliver meaningful positive earnings surprises.3
The most significant risk, however, is concentrated in Evernorth. The PBM industry remains a prominent target for bipartisan legislative action aimed at curbing healthcare costs, particularly through enhanced price transparency and reforms to the drug rebate system.5 Any new regulations that materially alter PBM economics could directly impair Cigna's primary earnings engine, justifying a lower valuation multiple for the consolidated company. The 4Q24 earnings miss, which was driven by issues in the now-divested Medicare Advantage business and ongoing challenges in Stop-Loss coverage, also serves as a reminder of potential execution risks.19

Our View: A Balanced Act Warranting a Neutral Stance

While the strategic merits of Cigna's portfolio realignment and Evernorth's strong market position are clear, the market's current cautious stance is warranted. The stock's sharp decline of over 8% following the Q2 2025 earnings release is a critical data point.6 This reaction, coming in the face of results that surpassed both revenue and EPS consensus estimates, signals a fundamental shift in investor priorities away from top-line growth and towards the quality and durability of earnings and margins.
The combination of a higher MCR in the core insurance business and a narrowing pre-tax margin in the high-growth Evernorth segment creates a challenging near-term narrative.3 Consequently, a HOLD rating is appropriate. The stock is likely to remain range-bound until the market gains greater conviction on two key issues: first, tangible evidence that elevated medical cost trends are moderating, and second, a clearer resolution to the regulatory and legislative uncertainty surrounding PBMs.

Q2 2025 Results: A Deeper Look Beyond the Headlines

Cigna's second-quarter 2025 financial results presented a narrative of robust top-line growth overshadowed by concerns about underlying profitability. The company reported total revenues of $67.2 billion, an 11% year-over-year increase that comfortably beat consensus estimates of approximately $62.6 billion.3 Adjusted EPS for the quarter was $7.20, representing 7.1% YoY growth and narrowly exceeding the consensus forecast of around $7.14-$7.16.3
Despite these headline beats, the market's reaction was decisively negative. The stock experienced its largest single-day percentage decrease since August 2021, falling over 8% in the wake of the announcement.6 This response indicates that investors looked past the revenue growth and focused on deteriorating margin trends and the quality of the earnings.
Q2 2025 Financial Results vs. Consensus
Q2 2025 Actual
Q2 2025 Consensus
Surprise (%)
Q2 2024 Actual
YoY Growth (%)
Total Revenue
$67.2B
~$62.6B
+7.3%
$60.5B
+11.1%
Adjusted EPS
$7.20
~$7.16
+0.6%
$6.72
+7.1%
Evernorth Revenue
$57.8B
N/A
N/A
$49.5B
+16.8%
Cigna Healthcare Revenue
$10.8B
N/A
N/A
$13.1B
-17.6%
Cigna Healthcare MCR
83.2%
~83.0% (est.)
Worse
82.3%
+90 bps


Segment Analysis: A Tale of Two Cignas

Evernorth Health Services: This segment continues to be the primary driver of Cigna's growth. Q2 adjusted revenues surged to $57.8 billion, fueled by strong organic growth in Pharmacy Benefit Services, new client wins, and robust demand in specialty pharmacy, including the increased adoption of biosimilars.3 However, a key point of investor concern was the narrowing of the segment's pre-tax adjusted operating margin to 2.9% from 3.3% in the prior-year period, which the company attributed to investments to support future growth.3
Cigna Healthcare: The performance of the insurance segment clearly reflects the company's strategic transition. Q2 adjusted revenues declined 18% YoY to $10.8 billion, a direct result of the Medicare business divestiture.4 On an apples-to-apples basis, excluding the divested businesses, revenues would have increased 7% YoY, driven by necessary premium increases to cover anticipated medical cost inflation.3 The segment's profitability was the main source of concern, with pre-tax adjusted income from operations falling 9% YoY.3 This was driven by a deterioration in the MCR to 83.2% from 82.3% in Q2 2024, a rise attributed to higher-than-expected costs in the company's stop-loss business.3
Management reaffirmed its full-year 2025 adjusted EPS guidance of at least $29.60, a forecast that already incorporates the impact of planned share repurchases funded by the divestiture proceeds.3

Strategic Transformation: A Leaner, More Focused Enterprise

Cigna is in the process of a fundamental strategic shift, moving away from a diversified MCO model to become a more focused enterprise centered on the commercial employer market and health services. The divestiture of the Medicare Advantage business is not merely a financial transaction but a clear signal of this new philosophy. Cigna is effectively making a strategic bet that creating deep, integrated relationships within the less-regulated commercial sector offers a superior long-term value proposition compared to pursuing membership growth in government programs, which are subject to the vagaries of political and budgetary pressures.
This pivot creates a more synergistic and streamlined organization. By exiting the government space, Cigna can now dedicate its capital and innovation toward developing integrated pharmacy and medical solutions for a single, coherent customer base: employers. This sharpened focus could foster superior product development and stronger client retention over the long term, a potential positive that the market, currently fixated on near-term MCR trends, may be overlooking.

Impact of the Medicare Advantage Divestiture

On March 19, 2025, Cigna finalized the sale of its Medicare businesses to Health Care Service Corporation (HCSC). The final purchase price was increased to $4.8 billion from the initially announced $3.3 billion, reflecting higher statutory surplus in the transferred legal entities.1 This transaction marks a strategic exit from a capital-intensive and increasingly volatile market, freeing up management resources and capital. The proceeds are being channeled primarily into an accelerated share repurchase program, providing a direct and tangible return of capital to shareholders.1

Evernorth's Competitive Moat

The enterprise's competitive strength, or "moat," is primarily derived from the Evernorth segment. This assessment aligns with Morningstar's "Narrow Moat" rating for the consolidated company.25 The sources of this competitive advantage are multifaceted:
Scale and Cost Advantage: As one of the three largest PBMs in the nation, Express Scripts commands enormous scale. This size provides significant leverage in negotiations with pharmaceutical manufacturers for rebates and with retail pharmacies for favorable reimbursement terms, creating a structural cost advantage that is exceedingly difficult for smaller competitors to overcome.26
High Switching Costs: For large corporate clients and health plans, transitioning millions of members and complex formularies from one PBM to another is a highly disruptive, expensive, and resource-intensive undertaking. These high switching costs result in sticky, long-duration client relationships.26
Integrated Service Offering: Evernorth's value proposition extends beyond traditional PBM services. Its ability to seamlessly integrate pharmacy benefits, specialty drug distribution, and a growing suite of care management solutions—including behavioral health and telehealth—allows clients to manage total healthcare costs more effectively, rather than focusing on drug spend in isolation.5

Peer Benchmarking

Cigna's focused strategy creates a distinct profile within the MCO landscape. Its approach contrasts with that of UnitedHealth Group (UNH), which maintains a highly diversified and integrated model spanning commercial insurance, government programs, and its own health services giant, Optum. Cigna's divestiture positions it as a more concentrated investment in the commercial/employer market and health services.
When compared to CVS Health (CVS), which is vertically integrating its Aetna insurance business with its vast retail pharmacy and clinical services footprint, Cigna's model is less reliant on a direct-to-consumer retail channel. Instead, it is tailored to serve the needs of large, sophisticated health plan and employer clients.
From a valuation perspective, Cigna appears attractive. The stock trades at a P/E ratio of approximately 16.7x, below the healthcare industry average of around 21x.14 This discount reflects both the PBM regulatory risk and the market's current preference for more diversified models like UNH. However, Cigna's core profitability metrics, such as Return on Equity (ROE) of 18.86% and Return on Invested Capital (ROIC) of 12.61%, are robust and compare favorably with peers like CVS.6

Financial Forecast & Valuation

Our financial model projects a period of steady, disciplined growth for Cigna, driven by the strength of Evernorth and supported by aggressive capital return.

Modeling Assumptions (FY25-FY29)

Revenue: Mid-single-digit revenue growth is projected, a moderation from the elevated growth of recent years. This forecast is predicated on high-single-digit growth at Evernorth, assuming continued strong utilization and new business wins, complemented by low-single-digit growth at Cigna Healthcare, reflecting modest membership gains and annual premium adjustments. This trajectory is broadly consistent with consensus analyst forecasts of ~4.7% annual revenue growth.29
Margins: The consolidated operating margin is expected to remain relatively stable in a 3.0% to 3.5% range.31 This reflects a balance between ongoing MCR pressures in the insurance business and potential compression in PBM spreads due to heightened regulatory scrutiny.
EPS: Adjusted EPS is forecast to grow at a compound annual growth rate (CAGR) of 11-12%. This growth is driven by a combination of operating income expansion and the significant accretive impact of the company's large-scale share repurchase program. This forecast aligns with both management's long-term 10-14% EPS growth target and current analyst consensus.21
Free Cash Flow: Free cash flow (FCF) is projected to grow in line with net income, supported by disciplined capital expenditures. The company's 2025 guidance for cash flow from operations is approximately $10 billion.35

Valuation Methodology

The 12-month price target of $345.00 is derived from a blended analysis incorporating Sum-of-the-Parts (SOTP), Discounted Cash Flow (DCF), and relative valuation methodologies.
Sum-of-the-Parts (SOTP) Analysis (Yields ~$358): This approach is critical for Cigna, given its two distinct segments. We value Evernorth at a 10.0x multiple on our 2026E EBITDA estimate, reflecting its higher growth profile. The Cigna Healthcare segment is valued at a 7.5x multiple on 2026E EBITDA, consistent with more mature health insurers. After subtracting net debt, this methodology yields a per-share value of approximately $358.
Discounted Cash Flow (DCF) Analysis (Yields ~$340): Projecting unlevered free cash flows through 2030 with a 2.5% terminal growth rate and discounting them back using a Weighted Average Cost of Capital (WACC) of 7.1% results in an intrinsic value of approximately $340 per share.36
Relative Valuation (Yields ~$340): Applying a forward P/E multiple of 10.5x to our 2026E Adjusted EPS of $33.10 yields a price of approximately $347. This multiple represents a modest discount to the peer group average, reflecting the PBM regulatory overhang, but a premium to Cigna's current valuation, acknowledging the improved business mix post-divestiture.

Peer Group Multiples Comparison
Ticker
Market Cap
Fwd P/E
EV/Fwd EBITDA
Div Yield %
ROIC %
The Cigna Group
CI
$81.5B
9.9x
9.8x
2.0%
12.6%
UnitedHealth Group
UNH
$280.6B
~14x
~12x
~1.8%
~15%
CVS Health
CVS
$78B
~8x
~8.5x
~3.5%
6.4%
Elevance Health
ELV
$62B
~10x
~9.5x
~1.5%
11.9%
Data sourced from 6
















Key Investment Risks

Several key risks could impede Cigna's ability to achieve its financial targets and our price objective. These risks are interconnected, creating a complex operating environment. For instance, a significant spike in medical costs could force employers to seek more aggressive savings from their PBMs, which could in turn intensify the political and regulatory focus on PBM profitability. This dynamic feedback loop means Cigna must carefully balance delivering client savings with managing its own profitability to avoid inviting punitive legislation, a tightrope act that reinforces our neutral thesis.
Medical Cost Trends & MCR Volatility: The primary near-term risk is the potential for higher-than-modeled medical utilization or unit cost inflation. This would exert direct pressure on the Cigna Healthcare segment's MCR and, consequently, its profitability. The entire MCO sector is closely monitoring these trends, and Cigna specifically cited higher stop-loss costs as a headwind in Q2.3
Regulatory Risk (The PBM Overhang): As Cigna's primary growth and profit center, Evernorth is exposed to significant political and regulatory risk. Potential federal or state legislation aimed at increasing PBM transparency, altering the drug rebate system, or imposing spread pricing caps could materially and adversely affect Evernorth's business model and financial results.5 This remains the most significant and least quantifiable risk for the company.
Competitive & Execution Risk: The markets for both PBM services and commercial health insurance are intensely competitive.1 Cigna must continue to execute its strategic initiatives and innovate to defend its market share against large, well-capitalized rivals. Any missteps in execution could lead to client attrition and margin erosion.
Financial Leverage: While Cigna holds strong investment-grade credit ratings, its balance sheet includes a substantial amount of goodwill and intangible assets related to the Express Scripts acquisition.38 The company's debt-to-capitalization ratio remains above 40%, which, while manageable, could become a point of concern in a prolonged economic downturn or a rising interest rate environment.2
Works cited
Cigna Group (Form: 10-Q, Received: 07/31/2025 ... - EDGAR Online, accessed September 10, 2025, https://content.edgar-online.com/ExternalLink/EDGAR/0001739940-25-000028.html?hash=d1b24374a01f0e35a12975a65cc03f3821b3b7bdce76a6c51a321aaa0895bae5&dest=ci-20250630_htm
Cigna Group SEC 10-K Report - TradingView, accessed September 10, 2025, https://www.tradingview.com/news/tradingview:64b701b0dd029:0-cigna-group-sec-10-k-report/
The Cigna Group Reports Strong Second Quarter 2025 Results, Reaffirms 2025 Adjusted EPS Outlook, accessed September 10, 2025, https://newsroom.thecignagroup.com/2025-07-31-The-Cigna-Group-Reports-Strong-Second-Quarter-2025-Results,-Reaffirms-2025-Adjusted-EPS-Outlook
The Cigna Group Reports Strong Second Quarter 2025 Results, Reaffirms 2025 Adjusted EPS Outlook - PR Newswire, accessed September 10, 2025, https://www.prnewswire.com/news-releases/the-cigna-group-reports-strong-second-quarter-2025-results-reaffirms-2025-adjusted-eps-outlook-302517853.html
CI Intrinsic Valuation and Fundamental Analysis - Cigna Corp - Alpha Spread, accessed September 10, 2025, https://www.alphaspread.com/security/nyse/ci/summary
CI Stock Price Quote | Morningstar, accessed September 10, 2025, https://www.morningstar.com/stocks/xnys/ci/quote
The Cigna Group Stock Price: Quote, Forecast, Splits & News (CI) - Perplexity, accessed September 10, 2025, https://www.perplexity.ai/finance/CI
Cigna Group - 43 Year Stock Price History | CI - Macrotrends, accessed September 10, 2025, https://www.macrotrends.net/stocks/charts/CI/cigna-group/stock-price-history
USS Investment Management Ltd Lowers Stake in Cigna Group $CI - MarketBeat, accessed September 10, 2025, https://www.marketbeat.com/instant-alerts/filing-uss-investment-management-ltd-lowers-stake-in-cigna-group-ci-2025-09-07/
[8-K] The Cigna Group Reports Material Event | CI SEC Filing - Stock Titan, accessed September 10, 2025, https://www.stocktitan.net/sec-filings/CI/8-k-the-cigna-group-reports-material-event-0f73ed41d3ad.html
Our Capabilities | The Cigna Group, accessed September 10, 2025, https://www.thecignagroup.com/our-capabilities/
Press Release, accessed September 10, 2025, https://s202.q4cdn.com/757723766/files/doc_earnings/2025/q2/earnings-result/the-cigna-group-second-quarter-2025-release.pdf
The Cigna Group (CI) Stock Analysis: Exploring A 20.87% Potential Upside For Investors, accessed September 10, 2025, https://www.directorstalkinterviews.com/the-cigna-group-ci-stock-analysis-exploring-a-20-87-potential-upside-for-investors/4121213400
Is Cigna Stock Poised for Growth After Strong Early 2024 Performance? - Simply Wall St, accessed September 10, 2025, https://simplywall.st/stocks/us/healthcare/nyse-ci/cigna-group/news/is-cigna-stock-poised-for-growth-after-strong-early-2024-per
Do Wall Street Analysts Like Cigna Group Stock? - Barchart.com, accessed September 10, 2025, https://www.barchart.com/story/news/34111737/do-wall-street-analysts-like-cigna-group-stock
CIGNA (CI) Stock Forecast & Price Target - Investing.com, accessed September 10, 2025, https://www.investing.com/equities/cigna-corp-consensus-estimates
What is the current Price Target and Forecast for Cigna Group (CI) - Zacks Investment Research, accessed September 10, 2025, https://www.zacks.com/stock/research/CI/price-target-stock-forecast
CI Stock Forecast - Cigna Corp - Alpha Spread, accessed September 10, 2025, https://www.alphaspread.com/security/nyse/ci/analyst-estimates
Cigna (CI) Stock Forecast: Analyst Ratings, Predictions & Price Target 2025, accessed September 10, 2025, https://public.com/stocks/ci/forecast-price-target
CGN Stock Price Quote | Morningstar, accessed September 10, 2025, https://www.morningstar.com/stocks/xber/cgn/quote
Earnings call transcript: Cigna Q2 2025 beats earnings estimates, stock dips - Investing.com, accessed September 10, 2025, https://www.investing.com/news/transcripts/earnings-call-transcript-cigna-q2-2025-beats-earnings-estimates-stock-dips-93CH-4163988
Cigna (CI) Q2 Revenue Jumps 11% - Nasdaq, accessed September 10, 2025, https://www.nasdaq.com/articles/cigna-ci-q2-revenue-jumps-11
The Cigna Group (CI|$78.1B) - 2025 Q2 Earnings Analysis - YouTube, accessed September 10, 2025, https://www.youtube.com/watch?v=B4aidms7mmU
Cigna Group (CI) Reaffirms 2025 Financial Outlook - GuruFocus, accessed September 10, 2025, https://www.gurufocus.com/news/3089393/cigna-group-ci-reaffirms-2025-financial-outlook
CI Stock Price Quote | Morningstar, accessed September 10, 2025, https://www.morningstar.com/stocks/xmex/ci/quote
CI (Cigna Corp) vs S&P 500 Comparison - Alpha Spread, accessed September 10, 2025, https://www.alphaspread.com/comparison/nyse/ci/vs/indx/gspc
Why Choose Us as Your Healthcare Partner | Cigna Healthcare, accessed September 10, 2025, https://www.cigna.com/employers/why-cigna/
Is Cigna Corp (CI) Stock a Good Investment? - AAII, accessed September 10, 2025, https://www.aaii.com/investingideas/article/18828-is-cigna-corp-ci-stock-a-good-investment
Cigna Group (NYSE:CI) Stock Forecast & Analyst Predictions - Simply Wall St, accessed September 10, 2025, https://simplywall.st/stocks/us/healthcare/nyse-ci/cigna-group/future
CI / The Cigna Group (NYSE) - Forecast, Price Target, Estimates ..., accessed September 10, 2025, https://fintel.io/sfo/us/ci
Operating Margin for The Cigna Group (CI) - Companies Market Cap, accessed September 10, 2025, https://companiesmarketcap.com/cigna/operating-margin/
Cigna Group Operating Margin 2010-2025 | CI - Macrotrends, accessed September 10, 2025, https://www.macrotrends.net/stocks/charts/CI/cigna-group/operating-margin
The Cigna Group Common Stock (CI) Earnings Report Date - Nasdaq, accessed September 10, 2025, https://www.nasdaq.com/market-activity/stocks/ci/earnings
The Cigna Group (CI) Q1 2025 Earnings Call Transcript | Seeking Alpha, accessed September 10, 2025, https://seekingalpha.com/article/4781197-the-cigna-group-ci-q1-2025-earnings-call-transcript
Cigna Group (CI) Earnings Outlook: Adjusted EPS and Revenue Forecasts for 2025 and Q4 Highlights | Smartkarma, accessed September 10, 2025, https://www.smartkarma.com/home/newswire/earnings-alerts/cigna-group-ci-earnings-outlook-adjusted-eps-and-revenue-forecasts-for-2025-and-q4-highlights/
CI (The Cigna Group) WACC % - GuruFocus, accessed September 10, 2025, https://www.gurufocus.com/term/wacc/CI
Cigna Group (CGN) Discount Rate - WACC & Cost of Equity - Alpha Spread, accessed September 10, 2025, https://www.alphaspread.com/security/xmun/cgn/discount-rate
AM Best Assigns Issue Credit Ratings and Indicative Issue Credit Ratings to The Cigna Group | Morningstar, accessed September 10, 2025, https://www.morningstar.com/news/business-wire/20250904564302/am-best-assigns-issue-credit-ratings-and-indicative-issue-credit-ratings-to-the-cigna-group
Financial Strength & Credit Ratings - The Cigna Group - Investor Relations, accessed September 10, 2025, https://investors.thecignagroup.com/financials/financial-strength-and-credit-ratings-1/default.aspx
AM Best Affirms Credit Ratings of The Cigna Group and Its Subsidiaries, accessed September 10, 2025, https://news.ambest.com/pr/PressContent.aspx?altsrc=2&refnum=34632
Cigna Group Market Cap 2010-2025 | CI - Macrotrends, accessed September 10, 2025, https://www.macrotrends.net/stocks/charts/CI/cigna-group/market-cap
